Central modulation of rectal distension-induced blood pressure changes by alosetron, A 5-HT3 receptor antagonist

Digestive Diseases and Sciences

Volumn 44, Issue 1, 1999, Pages 20-24

  Miura, Masatake ^a,b   Curtis Lawson, D ^a,b   Clary, Erik M ^a,b   Mangel, Allen W ^a,b   Pappas, Theodore N ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

5 HT3 receptor antagonist; Alosetron; Irritable bowel syndrome; Rectal distension; Visceral nociception

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOG; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RECTUM; VASOMOTOR REFLEX; VISCERAL PAIN;

EID: 0032894361     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026633629141     Document Type: Article

References (21)

1. 1. Everhart JE, Renault PF: Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 100:998-1005, 1991
2. 2. Sandler RS: Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 99:409-415, 1990
3. 3. Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107:271-293, 1994
4. 4. Bueno L, Fioramonti J, Delvaux M, Frexinos J: Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations. Gastroenterology 112:1714-1743, 1997
5. 5. Camilleri M, Choi M-G: Irritable bowel syndrome. Aliment Pharmacol Ther 11:3-15, 1997
6. 6. Ritchie J: Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14:125-132, 1973
7. 7. Whitehead WE, Holtkotter B, Enck P, Hoelzi R, Holmes KD, Anthony J, Shabsin HS, Schuster MM: Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 98:1187-1192, 1990
8. 8. Ness TJ, Gebhart GF: Colorectal distention as a noxious visceral stimulus: Physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res 450:153-169, 1988
9. 9. Moss HE, Sanger GJ: The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distention. Br J Pharmacol 100:497-501, 1990
10. 10. Scott CM, Grundy D, Boissonade F, Bountra C: Alosetron inhibits the colorectal distention-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gastroenterology 112:A822, 1997
11. 11. Farthing MJG: 5-Hydroxytryptamine and 5-hydroxytryptamine-3 receptor antagonists. Scand J Gastroenterol 26(suppl 188):92-100, 1991
12. 12. Bardhan K, Bodemar G, Geldef H, Schultz E, Snell C, Darekar B: A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Gastroenterology 110:A630, 1996
13. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 7:175-180, 1993
14. 3 antagonism (ondansetron). Digestion 57:748-483, 1996
15. 3 receptors in rat brain using radioligand binding. Nature 330:746-748, 1982
16. 3 ligand, (3H)GR65630, to rat area postrema, vagus nerve and the brain of several species. Eur J Pharmacol 159:157-164, 1989
17. 17. Geoghegan JG, Lawson DC, Cheng CA, Pappas TN: Intracerebroventricular neuropeptide Y increases gastric acid secretion by decreasing tonic adrenergic inhibition of acid in dogs. Brain Res 635:118-124, 1994
18. 3 receptors are membrane ion channels. Nature 339:706-709, 1989
19. 19. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Foster E, Frezinos J: Effect of alosetron on colonic sensitivity in patients with irritable bowel syndrome. Gastroenterology 110:A665, 1996
20. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 35:477-480, 1990
21. 21. Foster JM, Houghton LA, Whorwell PJ: Alosetron slows colonic transit in patients with irritable bowel syndrome. Gastroenterology 112:A732, 1997